Výsledky vyhledávání - "Robin Bricker-Ford"

Novel 'High-dose Quad' Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report

Autor: Robin Bricker-Ford

Publikováno v: Journal of Pharmacy Practice. 36:458-462

Purpose: This case report outlines the successful eradication of chronic Helicobacter pylori ( H. pylori) infection using a novel, “high-dose quad” salvage therapy approach. Gastroenterologists may consider using this approach for patients who ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15adb1685001aba6aa67d71824584515
https://doi.org/10.1177/08971900211033143

Zobrazit plný text záznamu

Case Report of Hepatitis C Treatment Success in Male With Decompensated Cirrhosis and Polysubstance Abuse: The Important Role of the Pharmacist in Active Care Coordination

Autor: Robin Bricker-Ford, Amy Brumenschenkel

Publikováno v: Journal of Pharmacy Practice. 36:725-727

This is a case report of a man with decompensated cirrhosis and polysubstance abuse that was cured of chronic hepatitis C virus (HCV) infection through pharmacist active care coordination. The patient was prescribed Epclusa (sofosbuvir 400 mg/velpata

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc04301a88411caf1e5563a7e26ab4f5
https://doi.org/10.1177/08971900221074927

Zobrazit plný text záznamu

Cross-border antibiotic resistance patterns in trauma patients

Autor: Todd W. Costantini, Allison E. Berndtson, Gabrielle Z. Madsen, Raul Coimbra, Legrand Malany, Kevin Box, Alan Smith, Robin Bricker-Ford

Publikováno v: Surgery. 166:109-115

Background Antibiotic resistance is a growing problem worldwide, with differences in regional resistance patterns driven by variance in antibiotic stewardship. Hospitals along the United States-Mexico border increasingly identify resistance, raising

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b8116d2edce41045d9ac68c833aec6a
https://doi.org/10.1016/j.surg.2019.03.023

Zobrazit plný text záznamu

Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent

Autor: James H. McKerrow, Sharon L. Reed, Robin Bricker-Ford, Edmund V. Capparelli, M. John Rogers

Publikováno v: Antimicrobial agents and chemotherapy, vol 61, iss 1
Capparelli, EV; Bricker-Ford, R; Rogers, MJ; McKerrow, JH; & Reed, SL. (2017). Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi: 10.1128/AAC.01947-16. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/1cw9h5fc

Under an NIH priority to identify new drugs to treat class B parasitic agents, we performed high-throughput screens, which identified the activity of auranofin (Ridaura) against Entamoeba histolytica and Giardia intestinalis , major causes of water-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2801d37210a600d5389b45a8b31ad5b1
https://escholarship.org/uc/item/1cw9h5fc

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání